Kura and Mirati to evaluate combo therapy KO-2806 with adagrasib

San Diego, USA-based precision medicine firm Kura Oncology’s (Nasdaq: KURA) shares rose 4% to $8.31 yesterday, after it announced a research collaboration with Mirati Therapeutics (Nasdaq: MRTX), a commercial-stage targeted oncology company.

Under a clinical collaboration and supply agreement, they will evaluate the combination of KO-2806, a next-generation farnesyl transferase inhibitor (FTI), and adagrasib, a highly selective KRASG12C inhibitor, in patients with KRASG12C-mutated non-small cell lung cancer (NSCLC).

“Recent findings suggest that combining KO-2806 with adagrasib  can drive tumor regressions and enhance both duration and depth of antitumor response in pre-clinical models of KRASG12C-mutated NSCLC,” said Dr Stephen Dale, chief medical officer of Kura Oncology, adding: “This collaboration highlights the potential to address the urgent need for more durable and effective treatment options for patients with advanced solid tumors, and we look forward to collaborating with Mirati, an established leader in targeted oncology.”